Takeda Pharmaceutical Co (NYSE: TAK) reported a slight contraction in core financial metrics for the first quarter of fiscal year 2026. Core revenue declined 0.5% at constant exchange rates to 1.22 trillion yen, while core operating profit fell by the same margin.

The results reflect the company's ongoing investment in upcoming product launches and late-stage pipeline development, partially offset by savings from its transformation program. Management stated the performance aligns with expectations and keeps the company on track for full-year guidance.

Financial Performance

Revenue grew 10.2% to 1.22 trillion yen on an actual foreign exchange basis, driven by favorable currency movements that added 118.2 billion yen. Core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches contributed 4% of total revenue, expanding 22.6% at constant exchange rates.

Core earnings per share were 154 yen, down 11.8% at constant exchange rates, primarily due to a favorable tax position in the prior year. Reported operating profit stood at 201.4 billion yen. Gross profit was positive in the quarter, aided by favorable foreign exchange variance in cost of goods and a one-time divestiture-related milestone.

What the Numbers Show

The divergence between actual and constant exchange rate performance highlights significant currency tailwinds. While revenue rose 10.2% on an actual basis, the underlying organic decline of 0.5% indicates that operational growth from new launches and core brands was insufficient to offset losses from mature products like Vyvanse without currency assistance. This suggests near-term top-line resilience remains dependent on successful commercialization of new assets rather than existing portfolio momentum.

Pipeline and Launch Updates

Takeda advanced its Two-Horizon strategic roadmap with progress on three key assets:

• Orzafl: Received first approval in China for narcolepsy type 1. U.S. and Japan approvals are expected in Q2, with launches planned for the second half of 2026.
• Rusfertide: Obtained U.S. FDA priority review for polycythemia vera. Following Protagonist's opt-out from co-commercialization, Takeda holds exclusive global rights. Launch is expected in the second half of 2026.
• Zazositinib: An oral treatment for psoriasis demonstrated statistical superiority versus deucravacitinib in phase 3 studies. U.S. launch is targeted for the first half of 2027.

Strategic Initiatives

The company announced a collaboration with the Indonesian government to build plasma operations, starting with donation centers. This partnership aims to enhance Takeda’s plasma-derived therapies business and strengthen its global plasma ecosystem. Adjusted free cash flow included a $200 million payment to Protagonist related to the Rusfertide agreement. Takeda reaffirmed its commitment to delivering 650 to 750 billion yen in free cash flow for the full year.

The US Food and Drug Administration has accepted Takeda’s New Drug Application for zasocitinib to treat moderate-to-severe plaque psoriasis. The agency designated the submission for Priority Review.

The Prescription Drug User Fee Act target action date is set for the first quarter of calendar year 2027. The European Medicines Agency also accepted the marketing authorization application, initiating its review process.

Clinical Data Highlights

The filing relies on pivotal Phase 3 LATITUDE PsO 3001 and 3002 studies involving nearly 3,000 patients. The drug is a next-generation oral tyrosine kinase 2 inhibitor.

Zasocitinib demonstrated statistically significant improvements over placebo and active comparator apremilast. About 70% of patients achieved clear or almost clear skin at week 16.

Efficacy in High-Impact Sites

The data showed high levels of skin clearance in hard-to-treat areas. Scalp-specific responses reached 77% in study 3001 and 74% in study 3002. Nail and palmoplantar responses also met secondary endpoints.

Safety profiles remained consistent with previous studies. The most common adverse events included upper respiratory tract infection at 10.1%, nasopharyngitis at 6.2%, and acne at 6.5%. No new safety signals were identified.

What the Numbers Show

Zasocitinib achieved complete skin clearance (sPGA 0) in 40% of patients in the primary study, compared to 8% for apremilast and less than 1% for placebo. This divergence highlights the potential for superior efficacy in achieving total lesion resolution compared to existing oral therapies.

Financial Impact

Takeda stated the NDA filing has no significant impact on the full-year consolidated financial forecast for the fiscal year ending March 31, 2027. The company plans to submit additional applications to global regulatory authorities.